Articles tagged with Pancreatic Cancer
Researchers discovered that pancreatic cancer develops rapidly through a 'big bang' process, where key alterations occur simultaneously. This finding provides new insights into the disease's aggressiveness and may lead to improved diagnostic and therapeutic strategies.
Researchers identified dopamine receptor DRD2 as a key molecule in pancreatic cancer. Blocking the receptor inhibited cancer growth, while its blockade also slowed tumor growth in mice.
A recent study published in Cell found that gamma delta T cells prevent tumor-fighting immune cells from attacking pancreatic tumors. This infighting makes immunotherapy less effective, with only 8% of people surviving five years after diagnosis.
Researchers at Florida Atlantic University have discovered a natural compound, leiodermatolide, that inhibits cancer cell growth and blocks division using low concentrations. The compound has shown significant tumor reduction in a mouse model of metastatic pancreatic cancer.
Pancreatic cancer cells use stellate cells to scavenge for energy, increasing mitochondrial metabolism and tumor cell growth. Alanine is the key fuel source that promotes tumor proliferation.
A new approach using patient-derived cell lines has revealed that pancreatic tumors have diverse genetic mutations, making it challenging to target treatments. The study suggests that personalized medicine can be improved by testing drugs against each patient's specific tumor genetics.
A new drug therapy has been developed that targets pancreatic cancer cells by reducing their antioxidant levels, mimicking the suppression of NRF2. This approach has shown promise in preclinical studies and could provide a novel treatment option for this devastating disease.
Cancer Research UK has tripled its investment in pancreatic cancer research, aiming to improve diagnosis and treatment. The charity hopes to develop better treatments and improve survival rates for patients affected by the disease.
A study published in GIE: Gastrointestinal Endoscopy found that patients with pancreatic cysts are at a significantly increased risk of developing pancreatic cancer, with an estimated 19.64 times higher risk compared to those without cysts.
Researchers have found that a combination of immunotherapy and FAK inhibitors can improve survival times in mice with pancreatic cancer. The study suggests that targeting fibrous tissue in tumors may render them more responsive to immune therapies.
Researchers developed a rapid screening technique to analyze human tumors transplanted into mice, identifying WDR5 as a new culprit in pancreatic cancer. The study found that WDR5 protects tumors from DNA damage and works with the previously known cancer-promoting gene Myc to help tumors thrive.
Researchers developed an innovative imaging model to track drug resistance and identify a new therapeutic target for pancreatic cancer. The study revealed that the Musashi gene plays a critical role in promoting aggressive disease and found effective antisense inhibitors against Msi, halting tumor growth and improving survival.
A phase II clinical study found a 32% clinical benefit in pancreatic cancer patients with BRCA mutation, including one complete response and two partial responses. The drug's acceptable safety profile suggests it may be an option earlier in the treatment course for some patients.
Researchers identify human satellite II (HSATII) RNA as a promising early detection method for pancreatic cancer, with significantly higher levels found in patients' blood serum. A pilot study validated the test's ability to detect pancreatic cancer and a precancerous lesion in two cohorts of patients.
Researchers discovered that pancreatic cancers acquire metastatic capacity before transforming into cancer cells. Low miR-192 levels in tumor tissue are associated with rapidly progressing disease. miR-192 may serve as a clinical marker and potential therapeutic target for pancreatic cancer treatment.
Mayo Clinic researchers found that a combination of chemotherapy, radiation, and surgery can significantly improve survival rates for pancreatic cancer patients. Patients who received chemotherapy and/or radiation before surgery had better long-term outcomes than those who did not, with median survival times approaching four years.
Researchers have found that a combination of vitamin A and chemotherapy can reduce cancer cell proliferation and invasion in pancreatic cancer. The approach targets both cancer cells and surrounding stromal cells, blocking multiple cell signalling pathways used by cancer cells to become aggressive.
The Damon Runyon Cancer Research Foundation has selected five physician-scientists to receive the Physician-Scientist Training Award, providing them with resources to pursue cancer research. The awardees will receive grants totaling $2.3 million to aid their work in addressing the growing need for cancer research.
Researchers discovered that high-pressure environments in solid tumors, fueled by hyaluronic acid, hinder drug delivery. Treatment with an enzyme that breaks down hyaluronic acid can restore vessel expansion and improve treatment outcomes for drug-resistant cancers.
A new study found that online information about pancreatic cancer is often written at a reading level beyond the sixth grade, making it inaccessible to the general population. The research highlights the need for accurate and understandable health information to empower patients in making informed decisions about their care.
Websites geared towards more educated groups struggle to communicate with the general population. Nonprofit, academic, and government websites have higher accuracy but are harder to read. Healthcare professionals should actively evaluate online resources for their patients.
A randomized study found that chemoradiotherapy did not improve overall survival compared to chemotherapy in patients with locally advanced pancreatic cancer, contradicting prior expectations. The study also showed no significant difference between gemcitabine and gemcitabine plus erlotinib treatments.
Researchers at Purdue University have discovered a link between cholesterol metabolism and pancreatic cancer spread, pointing to potential new treatment using drugs for atherosclerosis. Controlling cholesterol metabolism reduces tumor growth and metastasis in mice.
A new study has found a direct link between pancreatic cancer and certain mouth bacteria, specifically Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans. Men and women with these bacteria in their oral microbiome were at least 50% and 59% more likely to develop pancreatic cancer, respectively.
Scientists have identified a mechanism behind pancreatic cancer's resistance to certain drugs and found a way to block it, making the cancer susceptible to formerly ineffective therapies. By targeting a protein called HuR, researchers can revive abandoned drugs and develop more effective combination therapies.
Researchers at the University of Liverpool have identified a critical role for stromal cells in the spread of pancreatic cancer to the liver. The study found that the protein granulin plays a key role in facilitating this process, and that targeting its expression may hold the key to stopping cancer from spreading.
A phase 1b clinical trial shows that an experimental therapy can control pancreatic cancer tumors well enough to make patients eligible for surgery. The treatment, PF-04136309, was found to be safe and effective when combined with chemotherapy.
The American Cancer Society has awarded nearly $44 million in grants to 103 researchers across the US. New grants focus on immunotherapy, DNA repair pathways, and metastasis, while existing grants support programs for adolescents and young adults with cancer.
Researchers at Beth Israel Deaconess Medical Center have identified a 5-gene classifier that can accurately detect early stages of pancreatic cancer, offering hope for earlier diagnosis and treatment. The classifier achieved high sensitivity and specificity rates in training and validation datasets.
Researchers have identified a link between adult-onset diabetes and certain cancers, highlighting the role of bromodomain (BRD) proteins. The study suggests that targeting BET proteins may be beneficial for both conditions.
Researchers at the University of Oklahoma have identified a gene target called GCNT3 that may offer promise in improving the treatment of pancreatic cancer. By targeting this gene, they theorized that multiple mucins could be shut down simultaneously, breaking down cancer's protective barrier.
Researchers have discovered a novel role for CD40 antibodies in re-educating macrophages to break down the tumor microenvironment, allowing chemotherapy to target pancreatic cancer more effectively. The optimal timing of delivery is critical, with chemotherapy being most effective when administered five days after CD40 treatment.
Researchers develop integrase-defective lentiviral vector to deliver chemotherapy-sensitizing gene to pancreatic tumor cells, reducing risk of insertional mutagenesis. The system enables high efficacy delivery of the gene that encodes for DCK protein to cancer cells, making them more sensitive to chemotherapeutic drug gemcitabine.
Research breakthrough reveals pancreatic tumours often lose miR-137 expression, triggering uncontrolled cell growth and cancer. Restoring normal miR-137 levels induces senescence and stops cells from spreading.
A new study reveals that pancreatic cancer is composed of four distinct subtypes, each with its own unique genetic profile and treatment possibilities. These findings have significant implications for diagnosis and treatment, potentially allowing for more accurate prognoses and targeted therapies.
A new study suggests that patients with resectable pancreatic cancer should receive at least 6 months of adjuvant chemotherapy to reduce distant disease recurrences and improve overall survival. Chemotherapy, but not chemoradiotherapy, significantly reduces the incidence of distant recurrence.
A new study by Texas Tech University Health Sciences Center El Paso found that a compound in neem leaves can stop pancreatic cancer growth and metastasis without harming normal cells. The researchers observed a 70% reduction in cancer cell migration and invasion, as well as an 80% drop in cancer cell colonies.
The charity has funded 40 research projects worth over £6 million, including grants for innovative treatments and personalised medicine approaches. Six new projects aim to develop imaging techniques, epigenetic biomarkers, and targeted therapies to improve patient outcomes.
Researchers at UT Southwestern Medical Center have discovered that CDK4/6 inhibitors alter the metabolism of pancreatic cancer cells, revealing a biologic vulnerability. By targeting altered tumor metabolism with other drugs, it may be possible to positively impact cancer treatment.
Researchers found that metformin decreases inflammation and fibrosis in pancreatic cancer, which may be most prevalent in overweight and obese patients. The study also identified a potential biomarker for response to metformin treatment based on patient body weight.
The UK's first national tissue bank aims to develop new treatments and improve patient outcomes for pancreatic cancer. The Tissue Bank will store high-quality samples from consenting patients, enabling researchers to test ideas and validate their research more effectively.
A study published in the British Journal of Cancer found that higher magnesium intake may lower the risk of pancreatic cancer. Researchers analyzed data from over 66,000 men and women and discovered a significant association between magnesium consumption and reduced pancreatic cancer incidence.
Researchers at MD Anderson Cancer Center have developed a new liquid biopsy technique that can analyze tumor genes from blood samples using exosomes, providing a non-invasive alternative to traditional biopsies. The approach has the potential to improve prognosis, guide targeted therapy, and monitor treatment progress.
Researchers found CTCs in 100% of patients with suspected tumors, but only 4% detected through peripheral blood. Portal vein samples provided more accurate tumor cell information, enabling better clinical decisions. The test could help predict patient outcomes and guide treatment options.
A study found that socioeconomic factors like race, ethnicity, insurance status, and geographic location affect the likelihood of undergoing surgery for early-stage pancreatic cancer. Patients who underwent resection had improved disease-specific survival compared to those who did not, with regional differences in survival rates observed.
Researchers at IUPUI developed a nanotech-based sensor to detect microRNAs in blood, enabling early cancer diagnosis and potentially improving treatment outcomes. The sensor's ultrasensitivity allows for the detection of minute changes in microRNA concentrations.
A new study developed a potential test to sort out precancerous pancreatic cysts from harmless ones, with an accuracy rate of up to 98 percent. The test combines genetic markers and clinical evaluation, potentially helping patients avoid unnecessary surgery.
Researchers discovered peptides that inhibit metastatic spreading and even lead to regression of existing metastases in pancreatic cancer models. The CD44v6 protein drives the spread of tumor cells, but small segments of the protein can be successfully inhibited by peptides.
Researchers are developing new technologies to analyze pancreatic tumor super-enhancers and testing therapies targeting these signals in clinical trials. The goal is to reprogram cancer cells or create vulnerabilities that can be exploited with combination drug therapies.
A team of top researchers will focus on reprogramming pancreatic tumor biology using cutting-edge technology and developing new SE-targeted drugs. The goal is to dial up sensitivity to chemotherapy and push tumors into lasting remission.
A team of top researchers, led by TGen's Dr. Daniel D. Von Hoff, aims to develop therapies that greatly improve patient survival. They will focus on reprogramming the 'super enhancers' in cancer cells to stop tumor growth and offer novel treatments for patients with pancreatic cancer.
A recent study by Mayo Clinic reveals that only one in five US pancreatic cancer patients receive the CA 19-9 tumor marker test at diagnosis, which can help predict treatment outcomes and guide personalized treatment. The test eliminates negative effects on survival when chemotherapy is administered before surgery.
A new study by Fred Hutchinson Cancer Center researchers found that immunotherapy can boost survival from pancreatic cancer by more than 75% in mice, even without chemotherapy or radiation. The therapy targets mesothelin, a protein overproduced by virtually all pancreatic tumors.
Researchers have discovered a genomic molecular fingerprint, signature 3, that highlights certain gastric cancers susceptible to treatment with platinum drugs or PARP inhibitor drugs. This biomarker could guide targeted therapy for breast, ovarian and pancreatic cancers as well.
New data from clinical trials at Penn Medicine demonstrate the clinical benefits of proton therapy for patients with advanced lung, pancreatic, and spine cancers. Proton therapy has been shown to reduce toxicities and improve survival rates compared to conventional radiation therapy.
UT Southwestern researchers have developed a classification model for cancers caused by KRAS, the most frequently mutated gene in cancer. The model helps predict the propensity of different KRAS mutants to signal through RAF kinase and could lead to more effective targeted therapies.
A Binghamton University biochemist has discovered a method to fight cancer by attacking only cancer cells and potentially reducing side effects. Hedgehogs, which normally turn off in mature cells, somehow re-activate in certain cancers, leading to uncontrolled cell growth.
Researchers have found that a protein called FAK plays a key role in the development of pancreatic neuroendocrine tumors. A two-drug combination has been shown to be more effective than everolimus alone in killing cancer cells and reducing tumor volume.
A combination of two drugs has been found to shrink pancreatic tumors in laboratory mice. The treatment, which targets the cell's DNA rather than proteins, also slowed the growth of human lung cancer cells. Researchers are now working to test this treatment in humans with pancreatic cancer.
A five-year programme will focus on developing miniscule technology to deliver drugs directly to cancer sites, improving chemotherapy effectiveness. The project tackles an important area around drug delivery in pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.